Kwarlay.com

Navigating the News Maze with Clarity

Medicine

RemeGen's Antibody-Drug Conjugate Gets FDA Fast Track Designation for Ovarian Cancer

RC88 is under evaluation for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.

LEAVE A RESPONSE

Your email address will not be published. Required fields are marked *